Vectura was studying VR475, a drug-device combination consisting of budesonide delivered by Vectura's proprietary nebulizer inhalation system as a treatment for adolescent and adult patients with severe uncontrolled asthma.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,